• Pharmacovigilance
  • Contact
    •

    Win Medica - The leading greek pharmaceutical company

    Our Portfolio

    87+ pharmaceutical products

    Prescription medicines, OTC products, medical devices and consumer health - all registered and commercialised for the Greek market.

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • Clear
    •
    • A

    • ABIRATERONE ACCORD

      Hormone antagonists and related agents

      Film-coated tablet

      Active substance Abiraterone acetate
      Form/Strength Film-coated tablet
      Packaging 500 MG/TAB
      Therapeutic area L02BX03
      PIL (Patient leaflet) 500 MG/TAB

    • ABSKEN

      Other drugs for constipation

      Film-coated tablets

      Active substance Προυκαλοπρίδη
      Form/Strength Film-coated tablets
      Packaging 1mg, 2mg
      Therapeutic area A06AX05
      PIL (Patient leaflet) 1mg, 2mg

    • ACCOFIL

      Colony stimulating factors

      Solution for injection/infusion in pre-filled syringe

      Active substance FILGRASTIM
      Form/Strength Solution for injection/infusion in pre-filled syringe
      Packaging 30 MU/0,5 ML, 48 MU/0,5 ML
      Therapeutic area L03AA02
      PIL (Patient leaflet) 30 MU/0,5 ML, 48 MU/0,5 ML

    • AGGRAFIBAN

      Platelet aggregation inhibitors excl. heparin

      Concentrate for solution for infusion

      Active substance TIROFIBAN HYDROCHLORIDE MONOHYDRATE
      Form/Strength Concentrate for solution for infusion
      Packaging 0.25 MG/ML
      Therapeutic area B01AC17
      PIL (Patient leaflet) 0.25 MG/ML

    • ALYMSYS

      Monoclonal antibodies

      Concentrate for solution for infusion

      Active substance BEVACIZUMAB
      Form/Strength Concentrate for solution for infusion
      Packaging 25 MG/ML
      Therapeutic area L01FG01
      PIL (Patient leaflet) 25 MG/ML

    • AMBRISENTAN ACCORD

      Other antihypertensives

      Film-coated tablet

      Active substance AMBRISENTAN
      Form/Strength Film-coated tablet
      Packaging 5 MG/TAB, 10 MG/TAB
      Therapeutic area C02KX02
      PIL (Patient leaflet) 5 MG/TAB, 10 MG/TAB

    • AMODUO

      Beta blocking agents other combinations

      Tablet

      Active substance BISOPROLOL FUMARATE & AMLODIPINE BESYLATE
      Form/Strength Tablet
      Packaging (5+5) MG/TAB, (10+5) MG/TAB, (5+10) MG/TAB, (10+10) MG/TAB
      Therapeutic area C07FB07
      PIL (Patient leaflet) (5+5) MG/TAB, (10+5) MG/TAB, (5+10) MG/TAB, (10+10) MG/TAB

    • ANIDULAFUNGIN/ACCORD

      Other antimycotics for systemic use

      Powder for concentrate for solution for infusion

      Active substance ANIDULAFUNGIN
      Form/Strength Powder for concentrate for solution for infusion
      Packaging 100 MG/VIAL
      Therapeutic area J02AX06
      PIL (Patient leaflet) 100 MG/VIAL

    • APREMILAST ACCORD

      Selective immunosuppressants

      Film-coated tablet

      Active substance APREMILAST
      Form/Strength Film-coated tablet
      Packaging 10 MG/TAB, 20 MG/TAB, 30 MG/TAB
      Therapeutic area L04AA32
      PIL (Patient leaflet) 10 MG/TAB, 20 MG/TAB, 30 MG/TAB

    • APREPITANT/WIN MEDICA

      Other antiemetics

      Hard capsules

      Active substance Aprepitant
      Form/Strength Hard capsules
      Packaging 80 mg/caps, 125 mg/caps, (125 mg/caps +80 mg/caps)
      Therapeutic area A04AD12
      PIL (Patient leaflet) 80 mg/caps, 125 mg/caps, (125 mg/caps +80 mg/caps)

    • ARSENIC TRIOXIDE ACCORD

      Other antineoplastic agents

      Concentrate for solution for infusion

      Active substance ARSENIC TRIOXIDE
      Form/Strength Concentrate for solution for infusion
      Packaging 1 MG/ML
      Therapeutic area L01XX27
      PIL (Patient leaflet) 1 MG/ML

    • AXITINIB ACCORD

      Protein kinase inhibitors

      Film-coated tablet

      Active substance AXITINIB
      Form/Strength Film-coated tablet
      Packaging 1 MG, 5 MG
      Therapeutic area L01EK01
      PIL (Patient leaflet) 1 MG, 5 MG

    • AZACITIDINE ACCORD

      Antimetabolites

      Powder for suspension for injection

      Active substance AZACITIDINE
      Form/Strength Powder for suspension for injection
      Packaging 25 MG/ML
      Therapeutic area L01BC07
      PIL (Patient leaflet) 25 MG/ML
    • B

    • BENDAMUSTINE / ACCORD

      Nitrogen mustard analogues

      Powder for concentrate for solution for infusion / Concentrate for solution for infusion

      Active substance BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
      Form/Strength Powder for concentrate for solution for infusion / Concentrate for solution for infusion
      Packaging 2,5 MG/ML, C/S.SOL.IN 25MG/ML
      Therapeutic area L01AA09
      PIL (Patient leaflet) 2,5 MG/ML, C/S.SOL.IN 25MG/ML

    • BORTEZOMIB ACCORD

      Proteasome inhibitors

      Powder for solution for injection

      Active substance BORTEZOMIB
      Form/Strength Powder for solution for injection
      Packaging 3,5 MG/VIAL
      Therapeutic area L01XG01
      PIL (Patient leaflet) 3,5 MG/VIAL
    • C

    • CABAZITAXEL ACCORD

      Taxanes

      Concentrate for solution for infusion

      Active substance CABAZITAXEL
      Form/Strength Concentrate for solution for infusion
      Packaging 20 MG/ML
      Therapeutic area L01CD04
      PIL (Patient leaflet) 20 MG/ML

    • CAMCEVI

      Gonadotropin releasing hormone analogues

      Prolonged-release suspension for injection (INJ.SU.PRO)

      Active substance LEUPRORELIN
      Form/Strength Prolonged-release suspension for injection (INJ.SU.PRO)
      Packaging 42MG/PF.SYR
      Therapeutic area L02AE02
      PIL (Patient leaflet) 42MG/PF.SYR

    • CAPECITABINE ACCORD

      Antimetabolites

      Film-coated tablet

      Active substance CAPECITABINE
      Form/Strength Film-coated tablet
      Packaging 150 MG/TAB, 300 MG/TAB, 500 MG/TAB
      Therapeutic area L01BC06
      PIL (Patient leaflet) 150 MG/TAB, 300 MG/TAB, 500 MG/TAB

    • CETILAR

      Product page CETILARView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • CILOS

      Platelet aggregation inhibitors excl. heparin

      Tablet

      Active substance CILOSTAZOL
      Form/Strength Tablet
      Packaging 50 MG/TAB, 100 MG/TAB
      Therapeutic area B01AC23
      PIL (Patient leaflet) 50 MG/TAB, 100 MG/TAB

    • COMBIPRESS

      Angiotensin II antagonists and calcium channel blockers

      Film-coated tablet (F.C.TAB)

      Active substance AMLODIPINE BESYLATE IRBESARTAN
      Form/Strength Film-coated tablet (F.C.TAB)
      Packaging (5+150)MG/TAB, (10+150)MG/TAB, (10+300)MG/TAB, (5+300)MG/TAB
      Therapeutic area C09DB05
      PIL (Patient leaflet) (5+150)MG/TAB, (10+150)MG/TAB, (10+300)MG/TAB, (5+300)MG/TAB

    • COMBIPRESS PLUS

      Angiotensin II antagonists calcium channel blockers and diuretics

      Film-coated tablet (F.C.TAB)

      Active substance AMLODIPINE BESYLATE + IRBESARTAN + HYDROCHLOROTHIAZIDE
      Form/Strength Film-coated tablet (F.C.TAB)
      Packaging (5 + 300 + 12,5) MG/TAB, (10 + 300 + 12,5) MG/TAB
      Therapeutic area C09DX07
      PIL (Patient leaflet) (5 + 300 + 12,5) MG/TAB, (10 + 300 + 12,5) MG/TAB
    • D

    • DABIGATRAN ETEXILATE ACCORD

      Direct thrombin inhibitors

      Hard capsule

      Active substance Dabigatran Etexilate
      Form/Strength Hard capsule
      Packaging 110 MG/TAB, 150 MG/TAB
      Therapeutic area B01AE07
      PIL (Patient leaflet) 110 MG/TAB, 150 MG/TAB

    • DAPTOMYCIN / ACCORDPHARMA

      Other antibacterials

      Powder for solution for injection/solution for infusion

      Active substance DAPTOMYCIN
      Form/Strength Powder for solution for injection/solution for infusion
      Packaging 350 MG, 500 MG
      Therapeutic area J01XX09
      PIL (Patient leaflet) 350 MG, 500 MG

    • DEFERASIROX ACCORD

      Iron chelating agents

      Film-coated tablet

      Active substance DEFERASIROX
      Form/Strength Film-coated tablet
      Packaging 90 MG/TAB, 180 MG/TAB, 360 MG/TAB
      Therapeutic area V03AC03
      PIL (Patient leaflet) 90 MG/TAB, 180 MG/TAB, 360 MG/TAB

    • DEXAMEZONE

      Glucocorticoids

      Tablet

      Active substance Δεξαμεθαζόνη
      Form/Strength Tablet
      Packaging 4 MG, 8 MG, 20 MG
      Therapeutic area H02AB02
      PIL (Patient leaflet) 4 MG, 8 MG, 20 MG

    • DICLOSIDE

      Other centrally acting agents

      Solution for injection

      Active substance DICLOFENAC SODIUM / THIOCOLCHICOSIDE
      Form/Strength Solution for injection
      Packaging (75 + 4) MG / 4ML
      Therapeutic area M03BX55
      PIL (Patient leaflet) (75 + 4) MG / 4ML

    • DOCETAXEL ACCORD

      Taxanes

      Concentrate for solution for infusion

      Active substance DOCETAXEL
      Form/Strength Concentrate for solution for infusion
      Packaging 20 MG/1 ML, 80 MG/4 ML, 160 MG/8 ML
      Therapeutic area L01CD02
      PIL (Patient leaflet) 20 MG/1 ML, 80 MG/4 ML, 160 MG/8 ML
    • E

    • ELTROMBOPAG ACCORD

      Eltrombopag

      Film-coated tablet

      Active substance Eltrombopag
      Form/Strength Film-coated tablet
      Packaging 25MG, 50MG
      Therapeutic area B02BX05
      PIL (Patient leaflet) 25MG, 50MG

    • ENTECAVIR ACCORD

      Nucleoside and nucleotide reverse transcriptase inhibitors

      Film-coated tablet

      Active substance ENTECAVIR
      Form/Strength Film-coated tablet
      Packaging 0,5 MG/TAB, 1 MG/TAB
      Therapeutic area J05AF10
      PIL (Patient leaflet) 0,5 MG/TAB, 1 MG/TAB
    • F

    • FLECARDIA INJ.SOL.INF

      Class IC antiarrhythmics

      Solution for injection or infusion

      Active substance FLECAINIDE ACETATE
      Form/Strength Solution for injection or infusion
      Packaging 10 MG/ML (150mg/15ml vial)
      Therapeutic area C01BC04
      PIL (Patient leaflet) 10 MG/ML (150mg/15ml vial)

    • FLECARDIA PR.CAP

      Class IC antiarrhythmics

      Prolonged-release capsules

      Active substance FLECAINIDE ACETATE
      Form/Strength Prolonged-release capsules
      Packaging 100 MG/CAP, 200 MG/CAP
      Therapeutic area C01BC04
      PIL (Patient leaflet) 100 MG/CAP, 200 MG/CAP

    • FLUAD

      Influenza vaccines

      Suspension for injection in pre-filled syringe

      Active substance ΑΔΡΑΝΟΠΟΙΗΜΕΝΑ ΑΝΤΙΓΟΝΑ ΕΠΙΦΑΝΕΙΑΣ ΤΩΝ ΣΤΕΛΕΧΩΝ A(H1N1), A(H3N2), B ΑΝΟΣΟΕΝΙΣΧΥΜΕΝΩΝ ΜΕ MF59C.1
      Form/Strength Suspension for injection in pre-filled syringe
      Packaging 15 μg ΑΙΜΟΣΥΓΚΟΛΛΗΤΙΝΗ (ΑΠΟ ΚΑΘΕ ΣΤΕΛΕΧΟΣ) ΑΝΑ ΔΟΣΗ 0,5 ml
      Therapeutic area J07BB02
      PIL (Patient leaflet) 15 μg ΑΙΜΟΣΥΓΚΟΛΛΗΤΙΝΗ (ΑΠΟ ΚΑΘΕ ΣΤΕΛΕΧΟΣ) ΑΝΑ ΔΟΣΗ 0,5 ml

    • FLUCELVAX

      Influenza vaccines

      Suspension for injection in pre-filled syringe

      Active substance ΑΔΡΑΝΟΠΟΙΗΜΕΝΑ ΑΝΤΙΓΟΝΑ ΕΠΙΦΑΝΕΙΑΣ ΤΩΝ ΣΤΕΛΕΧΩΝ A-H1N1, A-H3N2, B ΠΟΛΛΑΠΛΑΣΙΑΣΜΕΝΑ ΣΕ ΚΥΤΤΑΡΑ
      Form/Strength Suspension for injection in pre-filled syringe
      Packaging 15 μg ΑΙΜΟΣΥΓΚΟΛΛΗΤΙΝΗ (ΑΠΟ ΚΑΘΕ ΣΤΕΛΕΧΟΣ) ΑΝΑ ΔΟΣΗ 0,5 ml
      Therapeutic area J07BB02
      PIL (Patient leaflet) 15 μg ΑΙΜΟΣΥΓΚΟΛΛΗΤΙΝΗ (ΑΠΟ ΚΑΘΕ ΣΤΕΛΕΧΟΣ) ΑΝΑ ΔΟΣΗ 0,5 ml

    • FULVESTRANT ACCORD

      Anti estrogens

      Solution for injection in pre-filled syringe

      Active substance FULVESTRANT
      Form/Strength Solution for injection in pre-filled syringe
      Packaging 250 MG/5ML
      Therapeutic area L02BA03
      PIL (Patient leaflet) 250 MG/5ML
    • G

    • GEMCITABINE ACCORD

      Antimetabolites

      Concentrate for solution for infusion

      Active substance GEMCITABINE HYDROCHLORIDE
      Form/Strength Concentrate for solution for infusion
      Packaging 100 MG/ML
      Therapeutic area L01BC05
      PIL (Patient leaflet) 100 MG/ML

    • GERDOFF

      Product page GERDOFFView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • GLICRON

      Sulfonylureas

      Modified-release tablet

      Active substance GLICLAZIDE
      Form/Strength Modified-release tablet
      Packaging 60 MG/TAB
      Therapeutic area A10BB09
      PIL (Patient leaflet) 60 MG/TAB

    • GLITACT

      Thiazolidinediones

      Tablet

      Active substance PIOGLITAZONE
      Form/Strength Tablet
      Packaging 15 MG/TAB, 30 MG/TAB, 45 MG/TAB
      Therapeutic area A10BG03
      PIL (Patient leaflet) 15 MG/TAB, 30 MG/TAB, 45 MG/TAB
    • H

    • HETRONIFLY

      PD-1/PD-L1 inhibitors

      Concentrate for solution for infusion

      Active substance SERPLULIMAB
      Form/Strength Concentrate for solution for infusion
      Packaging 10 MG/ML
      Therapeutic area L01FF12
      PIL (Patient leaflet) 10 MG/ML
    • I

    • IBUTOMOL

      Propionic acid derivatives

      Film-coated tablet

      Product page IBUTOMOLView
      Active substance IBUPROFEN & PARACETAMOL
      Form/Strength Film-coated tablet
      Packaging (200+500) MG/TAB
      Therapeutic area M01AE51
      PIL (Patient leaflet) (200+500) MG/TAB

    • ICATIBANT ACCORD

      Other hematological agents

      Solution for injection (INJ.SOL)

      Active substance ICATIBANT
      Form/Strength Solution for injection (INJ.SOL)
      Packaging 30MG/3ML
      Therapeutic area B06AC02
      PIL (Patient leaflet) 30MG/3ML

    • IMULDOSA

      Interleukin inhibitors

      - Solution for injection in pre-filled syringe / - Concentrate for solution for infusion

      Active substance Ustekinumab
      Form/Strength - Solution for injection in pre-filled syringe / - Concentrate for solution for infusion
      Packaging 45 MG, 90 MG, 130 MG
      Therapeutic area L04AC05
      PIL (Patient leaflet) 45 MG, 90 MG, 130 MG

    • INTERBION

      Second generation cephalosporins

      Film-coated tablet

      Active substance CEFUROXIME AXETIL
      Form/Strength Film-coated tablet
      Packaging 500 MG/TAB
      Therapeutic area J01DC02
      PIL (Patient leaflet) 500 MG/TAB

    • IRBEPRESS

      Angiotensin II antagonists plain

      Tablet

      Active substance IRBESARTAN
      Form/Strength Tablet
      Packaging 75 MG/TAB, 150 MG/TAB, 300 MG/TAB
      Therapeutic area C09CA04
      PIL (Patient leaflet) 75 MG/TAB, 150 MG/TAB, 300 MG/TAB

    • IRBEPRESS PLUS

      Angiotensin II receptor blockers (ARBs) and diuretics

      Film-coated tablet

      Active substance IRBESARTAN & HYDROCHLOROTHIAZIDE
      Form/Strength Film-coated tablet
      Packaging 150+12.5 MG/TAB, 300+12.5 MG/TAB, 300+25 MG/TAB
      Therapeutic area C09DA04
      PIL (Patient leaflet) 150+12.5 MG/TAB, 300+12.5 MG/TAB, 300+25 MG/TAB

    • IRINOTECAN ACCORD

      Other antineoplastic agents

      Concentrate for solution for infusion

      Active substance IRINOTECAN HYDROCHLORIDE TRIHYDRATE
      Form/Strength Concentrate for solution for infusion
      Packaging 20 MG/ML
      Therapeutic area L01CE02
      PIL (Patient leaflet) 20 MG/ML
    • J

    • JALRA

      DPP-4 inhibitors

      Film-coated tablet

      Active substance VILDAGLIPTIN
      Form/Strength Film-coated tablet
      Packaging 50 MG/TAB
      Therapeutic area A10BH02
      PIL (Patient leaflet) 50 MG/TAB

    • JUBEREQ

      Other drugs affecting bone structure

      Solution for injection

      Active substance DENOSUMAB
      Form/Strength Solution for injection
      Packaging 70 MG/ML
      Therapeutic area MO5BX04
      PIL (Patient leaflet) 70 MG/ML
    • L

    • LENALIDOMIDE ACCORD

      Other immunosuppressants

      Hard capsule

      Active substance LENALIDOMIDE
      Form/Strength Hard capsule
      Packaging 2.5 MG/CAP, 5 MG/CAP, 7.5 MG/CAP, 10 MG/CAP, 20 MG/CAP, 25 MG/CAP
      Therapeutic area L04AX04
      PIL (Patient leaflet) 2.5 MG/CAP, 5 MG/CAP, 7.5 MG/CAP, 10 MG/CAP, 20 MG/CAP, 25 MG/CAP

    • LEVOSIMENDAN

      Other cardiac preparations

      Concentrate for solution for infusion (C/S.SOL.IN)

      Active substance LEVOSIMENDAN
      Form/Strength Concentrate for solution for infusion (C/S.SOL.IN)
      Packaging C/S.SOL.IN 2.5MG/ML
      Therapeutic area C01CX08
      PIL (Patient leaflet) C/S.SOL.IN 2.5MG/ML
    • M

    • METHOFILL

      Other immunosuppressants

      Solution for injection in pre-filled syringe

      Active substance METHOTREXATE
      Form/Strength Solution for injection in pre-filled syringe
      Packaging 50 mg/mL
      Therapeutic area L04AX03
      PIL (Patient leaflet) 50 mg/mL

    • MIBEZET

      Other lipid modifying agents

      Tablet

      Active substance EZETIMIBE
      Form/Strength Tablet
      Packaging 10 MG/TAB
      Therapeutic area C10AX09
      PIL (Patient leaflet) 10 MG/TAB

    • MYSIMBA

      Anti obesity preparations

      Prolonged-release tablets

      Active substance ΝΑΛΤΡΕΞΟΝΗ / ΒΟΥΠΡΟΠΙΟΝΗ
      Form/Strength Prolonged-release tablets
      Packaging ΚΑΘΕ ΔΙΣΚΙΟ ΠΕΡΙΕΧΕΙ 8 MG ΥΔΡΟΧΛΩΡΙΚΗ ΝΑΛΤΡΕΞΟΝΗ ΚΑΙ 90 MG ΥΔΡΟΧΛΩΡΙΚΗ ΒΟΥΠΡΟΠΙΟΝΗ
      Therapeutic area A08AA62
      PIL (Patient leaflet) ΚΑΘΕ ΔΙΣΚΙΟ ΠΕΡΙΕΧΕΙ 8 MG ΥΔΡΟΧΛΩΡΙΚΗ ΝΑΛΤΡΕΞΟΝΗ ΚΑΙ 90 MG ΥΔΡΟΧΛΩΡΙΚΗ ΒΟΥΠΡΟΠΙΟΝΗ
    • N

    • NILOTINIB ACCORD

      Protein kinase inhibitors

      Hard capsule

      Active substance Nilotinib
      Form/Strength Hard capsule
      Packaging 150MG/CAP, 200MG/CAP
      Therapeutic area L01EA03
      PIL (Patient leaflet) 150MG/CAP, 200MG/CAP
    • O

    • ON CALL EXTRA

      Product page ON CALL EXTRAView
      Therapeutic area
      PIL (Patient leaflet)

    • ON CALL VIVID

      Product page ON CALL VIVIDView
      Therapeutic area
      PIL (Patient leaflet)

    • ORGOVYX

      Hormone antagonists and related agents

      Film-coated tablet (F.C.TAB)

      Active substance RELUGOLIX
      Form/Strength Film-coated tablet (F.C.TAB)
      Packaging 120MG/TAB
      Therapeutic area L02BX04
      PIL (Patient leaflet) 120MG/TAB

    • OSVYRTI

      Other drugs affecting bone structure

      Solution for injection in pre-filled syringe

      Active substance DENOSUMAB
      Form/Strength Solution for injection in pre-filled syringe
      Packaging 60 MG/ML
      Therapeutic area M05BX04
      PIL (Patient leaflet) 60 MG/ML

    • OTILAX

      Synthetic anticholinergics

      Film-coated tablet

      Active substance OTILONIUM BROMIDE
      Form/Strength Film-coated tablet
      Packaging 40 MG/TAB
      Therapeutic area A03AB06
      PIL (Patient leaflet) 40 MG/TAB

    • OTOCORT

      Corticosteroids and antiinfectives combinations

      Ear spray, emulsion

      Active substance NEOMYCIN SULFATE & DEXAMETHASONE & ACETIC ACID
      Form/Strength Ear spray, emulsion
      Packaging [195IU+(0,06+1,2)MG]/DOSE
      Therapeutic area S02CA06
      PIL (Patient leaflet) [195IU+(0,06+1,2)MG]/DOSE
    • P

    • PALONOSETRON ACCORD

      Serotonin antagonists

      Solution for injection

      Active substance PALONOSETRON HYDROCHLORIDE
      Form/Strength Solution for injection
      Packaging 250 MCG/5ML (50 MCG/1ML)
      Therapeutic area A04AA05
      PIL (Patient leaflet) 250 MCG/5ML (50 MCG/1ML)

    • PANTIUM

      Proton pump inhibitors

      Gastro-resistant tablet

      Active substance PANTOPRAZOLE SODIUM SESQUIHYDRATE
      Form/Strength Gastro-resistant tablet
      Packaging 40 MG/TAB
      Therapeutic area A02BC02
      PIL (Patient leaflet) 40 MG/TAB

    • PELGRAZ

      Colony stimulating factors

      Solution for injection

      Active substance PEGFILGRASTIM
      Form/Strength Solution for injection
      Packaging 6 MG/0,6ML PFS, 6 MG/0,6ML PFI
      Therapeutic area L03AA13
      PIL (Patient leaflet) 6 MG/0,6ML PFS, 6 MG/0,6ML PFI

    • PEMETREXED ACCORD CS.SOL.IN

      Folic acid analogues

      Concentrate for solution for infusion

      Active substance PEMETREXED
      Form/Strength Concentrate for solution for infusion
      Packaging 25 MG/VIAL
      Therapeutic area L01BA04
      PIL (Patient leaflet) 25 MG/VIAL

    • PIRFENIDONE/ACCORD

      Other immunosuppressants

      Film-coated tablet

      Active substance Pirfenidone
      Form/Strength Film-coated tablet
      Packaging 267 mg, 801 mg
      Therapeutic area L04AX05
      PIL (Patient leaflet) 267 mg, 801 mg

    • PLERIXAFOR ACCORD

      Other immunostimulants

      Solution for injection

      Active substance Plerixafor
      Form/Strength Solution for injection
      Packaging 20MG/ML, BT X 1 VIAL X 1.2ML
      Therapeutic area L03AX16
      PIL (Patient leaflet) 20MG/ML, BT X 1 VIAL X 1.2ML

    • POMALIDOMIDE ACCORD

      Other immunosuppressants

      Hard capsule

      Active substance Pomalidomide
      Form/Strength Hard capsule
      Packaging 1 MG/CAP, 2 MG/CAP, 3 MG/CAP, 4 MG/CAP
      Therapeutic area L04AX06
      PIL (Patient leaflet) 1 MG/CAP, 2 MG/CAP, 3 MG/CAP, 4 MG/CAP

    • POSACONAZOLE ACCORD

      Triazole derivatives

      Gastro-resistant tablet

      Active substance POSACONAZOLE
      Form/Strength Gastro-resistant tablet
      Packaging 100 MG/TAB
      Therapeutic area J02AC04
      PIL (Patient leaflet) 100 MG/TAB
    • R

    • REKOMB

      HMG CoA reductase inhibitors combinations

      Film-coated tablet (F.C. TAB)

      Active substance Rosuvastatin+Ezetimibe
      Form/Strength Film-coated tablet (F.C. TAB)
      Packaging (5+10)MG/TAB, (10+10)MG/TAB, (20+10)MG/TAB, (40+10)MG/TAB
      Therapeutic area C10BA06
      PIL (Patient leaflet) (5+10)MG/TAB, (10+10)MG/TAB, (20+10)MG/TAB, (40+10)MG/TAB

    • RETAFORM

      Biguanides

      Prolonged-release tablet

      Active substance METFORMIN HYDROCHLORIDE
      Form/Strength Prolonged-release tablet
      Packaging 500 MG/TAB, 750 MG/TAB, 1000 MG/TAB
      Therapeutic area A10BA02
      PIL (Patient leaflet) 500 MG/TAB, 750 MG/TAB, 1000 MG/TAB

    • ROSUVASTATIN / WINMEDICA

      HMG CoA reductase inhibitors

      Film-coated tablet

      Active substance ROSUVASTATIN CALCIUM
      Form/Strength Film-coated tablet
      Packaging 5 MG/TAB, 10 MG/TAB, 20 MG/TAB, 40 MG/TAB
      Therapeutic area C10AA07
      PIL (Patient leaflet) 5 MG/TAB, 10 MG/TAB, 20 MG/TAB, 40 MG/TAB

    • ROXEGO

      Direct factor Xa inhibitors

      Film-coated tablets

      Active substance RIVAROXABAN
      Form/Strength Film-coated tablets
      Packaging 10mg/δισκίο, 15mg/δισκίο, 20mg/δισκίο
      Therapeutic area B01AF01
      PIL (Patient leaflet) 10mg/δισκίο, 15mg/δισκίο, 20mg/δισκίο
    • S

    • SIDERAL DROPS

      Product page SIDERAL DROPSView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • SIDERAL FOLICO

      Product page SIDERAL FOLICOView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • SIDERAL FORTE

      Caps

      Product page SIDERAL FORTEView
      Form/Strength Caps
      Packaging 20 caps, 30 caps
      Therapeutic area
      PIL (Patient leaflet) 20 caps, 30 caps

    • SIDERAL SPORT

      Product page SIDERAL SPORTView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • SOFARGEN SPRAY - GEL

      Product page SOFARGEN SPRAY - GELView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • SONDELBAY

      Parathyroid hormones

      Solution for injection (INJ.SOL)

      Active substance TERIPARATIDE
      Form/Strength Solution for injection (INJ.SOL)
      Packaging 20MCG/80μL
      Therapeutic area H05AA02
      PIL (Patient leaflet) 20MCG/80μL

    • SORAFENIB ACCORD

      Protein kinase inhibitors

      Film-coated tablet

      Active substance Sorafenib (ως tosilate)
      Form/Strength Film-coated tablet
      Packaging 200 mg
      Therapeutic area L01EX02
      PIL (Patient leaflet) 200 mg

    • SUNITINIB ACCORD

      Protein kinase inhibitors

      Hard capsule

      Active substance SUNITINIB
      Form/Strength Hard capsule
      Packaging 12.5 MG/CAP, 25 MG/CAP, 37.5 MG/CAP, 50 MG/CAP
      Therapeutic area L01XE01
      PIL (Patient leaflet) 12.5 MG/CAP, 25 MG/CAP, 37.5 MG/CAP, 50 MG/CAP
    • T

    • TEMOZOLOMIDE ACCORD

      Alkylating agents

      Hard capsule

      Active substance TEMOZOLOMIDE
      Form/Strength Hard capsule
      Packaging 5 MG/CAP, 20 MG/CAP, 100 MG/CAP, 140 MG/CAP, 180 MG/CAP, 250 MG/CAP
      Therapeutic area L01AX03
      PIL (Patient leaflet) 5 MG/CAP, 20 MG/CAP, 100 MG/CAP, 140 MG/CAP, 180 MG/CAP, 250 MG/CAP

    • TENOFOVIR DISOPROXIL/ACCORDPHARMA

      Nucleoside and nucleotide reverse transcriptase inhibitors

      Film-coated tablets

      Active substance ΔΙΣΟΠΡΟΞΙΛΙΚΗ ΤΕΝΟΦΟΒΙΡΗ
      Form/Strength Film-coated tablets
      Packaging 245 MG
      Therapeutic area J05AF07
      PIL (Patient leaflet) 245 MG

    • TICAGROL

      Platelet aggregation inhibitors excl. heparin

      Film-coated tablet

      Active substance TICAGROL
      Form/Strength Film-coated tablet
      Packaging 60 MG/TAB, 90 MG/TAB
      Therapeutic area B01AC24
      PIL (Patient leaflet) 60 MG/TAB, 90 MG/TAB

    • TOKOVYS

      Drugs used in nicotine dependence

      Film-coated tablet

      Product page TOKOVYSView
      Active substance CYTISINICLINE
      Form/Strength Film-coated tablet
      Packaging 1,5 MG
      Therapeutic area N07BA04
      PIL (Patient leaflet) 1,5 MG

    • TOPOTECAN ACCORD

      Other antineoplastic agents

      Concentrate for solution for infusion

      Active substance TOPOTECAN HYDROCHLORIDE
      Form/Strength Concentrate for solution for infusion
      Packaging 1 MG/ML
      Therapeutic area L01CE01
      PIL (Patient leaflet) 1 MG/ML

    • TOPRESS

      Angiotensin II antagonists and calcium channel blockers

      Film-coated tablet

      Active substance OLMESARTAN MEDOXOMIL & AMLODIPINE BESYLATE
      Form/Strength Film-coated tablet
      Packaging (20+5) MG/TAB, (40+5) MG/TAB, (40+10) MG/TAB
      Therapeutic area C09DB02
      PIL (Patient leaflet) (20+5) MG/TAB, (40+5) MG/TAB, (40+10) MG/TAB

    • TOPRESS PLUS

      Angiotensin II antagonists calcium channel blockers and diuretics

      Film-coated tablet

      Active substance OLMESARTAN MEDOXOMIL & AMLODIPINE BESYLATE & HYDROCHLOROTHIAZIDE
      Form/Strength Film-coated tablet
      Packaging (20+5+12,5) MG/TAB, (40+5+12,5) MG/TAB, (40+5+25) MG/TAB, (40+10+12,5) MG/TAB, (40+10+25) MG/TAB
      Therapeutic area C09DX03
      PIL (Patient leaflet) (20+5+12,5) MG/TAB, (40+5+12,5) MG/TAB, (40+5+25) MG/TAB, (40+10+12,5) MG/TAB, (40+10+25) MG/TAB

    • TORMIS

      High ceiling diuretics

      Tablet

      Active substance TORASEMIDE
      Form/Strength Tablet
      Packaging 2,5 MG/TAB, 5 MG/TAB, 10 MG/TAB
      Therapeutic area C03CA04
      PIL (Patient leaflet) 2,5 MG/TAB, 5 MG/TAB, 10 MG/TAB
    • U

    • ULTRAMAG ORO

      Product page ULTRAMAG OROView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • URICHOFEB

      Preparations inhibiting uric acid production

      Film-coated tablet

      Active substance FEBUXOSTAT
      Form/Strength Film-coated tablet
      Packaging 80 MG/TAB, 120 MG/TAB
      Therapeutic area M04AA03
      PIL (Patient leaflet) 80 MG/TAB, 120 MG/TAB
    • V

    • VALETONINA

      Product page VALETONINAView
      Therapeutic area
      PIL (Patient leaflet) PIL (Patient leaflet)

    • VITREX - EASYDRIP

      Product page VITREX - EASYDRIPView
      Therapeutic area
      PIL (Patient leaflet)

    • VORICONAZOLE ACCORD

      Triazole derivatives

      Film-coated tablet

      Active substance VORICONAZOLE
      Form/Strength Film-coated tablet
      Packaging 200 MG/TAB
      Therapeutic area J02AC03
      PIL (Patient leaflet) 200 MG/TAB
    • Z

    • ZARATOR

      HMG CoA reductase inhibitors

      Film-coated tablet

      Active substance ATORVASTATIN CALCIUM TRIHYDRATE
      Form/Strength Film-coated tablet
      Packaging 10 MG/TAB, 20 MG/TAB, 40 MG/TAB
      Therapeutic area C10AA05
      PIL (Patient leaflet) 10 MG/TAB, 20 MG/TAB, 40 MG/TAB

    • ZATEVEN

      Combinations of various lipid modifying agents

      Tablet

      Active substance ATORVASTATIN CALCIUM TRIHYDRATE & EZETIMIBE
      Form/Strength Tablet
      Packaging (10+10) MG/TAB, (20+10) MG/TAB, (40+10) MG/TAB
      Therapeutic area C10BA05
      PIL (Patient leaflet) (10+10) MG/TAB, (20+10) MG/TAB, (40+10) MG/TAB

    • ZERCEPAC

      Monoclonal antibodies

      Powder for concentrate for solution for infusion

      Active substance TRASTUZUMAB
      Form/Strength Powder for concentrate for solution for infusion
      Packaging 60 MG/VIAL, 150 MG/VIAL, 420 MG/VIAL
      Therapeutic area L01FD01
      PIL (Patient leaflet) 60 MG/VIAL, 150 MG/VIAL, 420 MG/VIAL

    • ZOLSKETIL pegylated liposomal

      Anthracyclines and related substances

      Concentrate for dispersion for infusion (CO.DIS.INF)

      Active substance DOXORUBICIN HYDROCHLORIDE
      Form/Strength Concentrate for dispersion for infusion (CO.DIS.INF)
      Packaging 2MG/ML
      Therapeutic area L01DB01
      PIL (Patient leaflet) 2MG/ML

    • ZOMARIST

      Combinations of oral blood glucose lowering drugs

      Film-coated tablet

      Active substance VILDAGLIPTIN & METFORMIN HYDROCHLORIDE
      Form/Strength Film-coated tablet
      Packaging (50+850) MG/TAB, (50+1000) MG/TAB
      Therapeutic area A10BD08
      PIL (Patient leaflet) (50+850) MG/TAB, (50+1000) MG/TAB

    For Healthcare Professionals

    Access the HCP portal

    Dedicated resources, product information and support for healthcare professionals across Greece.

    Enter the portal

    For Pharma Companies

    Partner with us

    Looking to bring your products to the Greek market? Let's talk about a strategic partnership.

    Get in touch